Cantex Pharmaceuticals is a pharmaceutical company developing proprietary pharmaceuticals that improve the treatment of cancer. Its pipeline includes CX-01 and Dicopp, two product candidates targeting a variety of disease indications, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and metastatic pancreatic cancer.